Autologous cytolytic T lymphocytes recognize a MAGE‐1 nonapeptide on melanomas expressing HLA‐Cw* 1601

Human melanoma cell line MZ2‐MEL expresses several antigens recognized by autologous cytolytic T lymphocyte (CTL) clones. We reported previously the identification of a gene, named MAGE‐1, which codes for antigen MZ2‐E which is presented by HLA‐A1. Gene MAGE‐1 is expressed in many tumors of several types but not in normal tissues except for testis. We show here that gene MAGE‐1 directs the expression of another antigen recognized by CTL on the MZ2‐MEL cells. This antigen, which was named MZ2‐Bb, consists of MAGE‐1‐encoded peptide SAYGEPRKL bound to major histocompatibility molecule HLA‐Cw* 1601. The HLA‐Cw* 1601 allele was found to be expressed by 7 out of 99 individuals from a Caucasian population. Our results extend the range of tumor patients who could be eligible for immunization against MAGE antigens.

[1]  J. Bodmer,et al.  Nomenclature for Factors of the HLA System, 1994 , 1994, Human immunology.

[2]  F. Brasseur,et al.  Expression of mage genes by non‐small‐cell lung carcinomas , 1994, International journal of cancer.

[3]  H. Grey,et al.  Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[4]  P. Romero,et al.  Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes , 1994, The Journal of experimental medicine.

[5]  V. Engelhard,et al.  Structure of peptides associated with class I and class II MHC molecules. , 1994, Annual review of immunology.

[6]  P. Bruggen,et al.  Tumor antigens recognized by T lymphocytes. , 1994, Annual review of immunology.

[7]  S. H. van der Burg,et al.  In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild‐type p53 , 1993, European journal of immunology.

[8]  P. Coulie,et al.  The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas , 1993, The Journal of experimental medicine.

[9]  S. H. van der Burg,et al.  Identification of peptide sequences that potentially trigger HLA‐A2.1‐restricted cytotoxic T lymphocytes , 1993, European journal of immunology.

[10]  P. Romero,et al.  The human melanoma antigen-encoding gene, MAGE-1, is expressed by other tumour cells of neuroectodermal origin such as glioblastomas and neuroblastomas. , 1993, International journal of cancer.

[11]  H. Stauss,et al.  Identification of two cytotoxic T lymphocyte-recognized epitopes in the Ras protein , 1993, The Journal of experimental medicine.

[12]  J. Bodmer,et al.  Tissue typing the HLA-A locus from genomic DNA by sequence-specific PCR: comparison of HLA genotype and surface expression on colorectal tumor cell lines. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[13]  M. Aidoo,et al.  Molecular analysis of the association of HLA-B53 and resistance to severe malaria , 1992, Nature.

[14]  P. Chomez,et al.  Human gene MAGE-1, which codes for a tumor-rejection antigen, is expressed by some breast tumors. , 1992, International journal of cancer.

[15]  Catia,et al.  A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E , 1992, The Journal of experimental medicine.

[16]  P. Parham,et al.  Distinctive polymorphism at the HLA-C locus: implications for the expression of HLA-C , 1992, The Journal of experimental medicine.

[17]  S. Roman-Roman,et al.  An experimentally validated panel of subfamily‐specific oligonucleotide primers (Vα1‐w29/Vβ1‐w24) for the study of human T cell receptor variable V gene segment usage by polymerase chain reaction , 1992, European journal of immunology.

[18]  P. Chomez,et al.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.

[19]  Timothy E. Elliott,et al.  A quantitative assay of peptide‐dependent class I assembly , 1991, European journal of immunology.

[20]  B. Moss,et al.  An HLA-C-restricted CD8+ cytotoxic T-lymphocyte clone recognizes a highly conserved epitope on human immunodeficiency virus type 1 gag , 1991, Journal of virology.

[21]  H. Rammensee,et al.  Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules , 1991, Nature.

[22]  H. Schluesener,et al.  Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins , 1991, The Journal of experimental medicine.

[23]  T. Boon,et al.  Antigens recognized on a melanoma cell line by autologous cytolytic T lymphocytes are also expressed on freshly collected tumor cells , 1990, European journal of immunology.

[24]  R. Fauchet,et al.  Presence on a human melanoma of multiple antigens recognized by autologous CTL , 1989, International journal of cancer.

[25]  R. Demars,et al.  Restriction of Epstein-Barr virus-specific cytotoxic T cells by HLA-A, -B, and -C molecules. , 1989, Human immunology.

[26]  K. Kano,et al.  The structure and expression of genes encoding serologically undetected HLA-C locus antigens. , 1989, Journal of immunology.

[27]  R. Demars,et al.  Sequence and gene transfer analyses of HLA-CwBL18 (HLA-C blank) and HLA-Cw5 genes. Implications for the control of expression and immunogenicity of HLA-C antigens. , 1989, Journal of immunology.

[28]  M. Hansen,et al.  Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. , 1989, Journal of immunological methods.

[29]  T. Boon,et al.  Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[30]  C. Slingluff,et al.  Human cytotoxic T cells specific for autologous melanoma cells: successful generation from lymph node cells in seven consecutive cases. , 1988, Journal of the National Cancer Institute.

[31]  C. Slingluff,et al.  Autologous lymph node cell‐derived tumor‐specific cytotoxic t‐cells for use in adoptive immunotherapy of human melanoma , 1988, Cancer.

[32]  H. Ploegh,et al.  Allele and locus‐specific differences in cell surface expression and the association of HLA class I heavy chain with β2‐microglobulin: differential effects of inhibition of glycosylation on class I subunit association , 1988, European journal of immunology.

[33]  W. Linehan,et al.  Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  P. Chomez,et al.  Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and identification of the tum- mutation. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[35]  B. Seed,et al.  Molecular cloning of the CD2 antigen, the T-cell erythrocyte receptor, by a rapid immunoselection procedure. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[36]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[37]  R. Devos,et al.  Production of stable cytolytic T‐cell clones directed against autologous human melanoma , 1987, International journal of cancer.

[38]  T. Espevik,et al.  A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. , 1986, Journal of immunological methods.

[39]  A. McMichael,et al.  The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides , 1986, Cell.

[40]  L. G. Davis,et al.  Guanidine Isothiocyanate Preparation of Total RNA , 1986 .

[41]  L. G. Davis,et al.  Basic methods in molecular biology , 1986 .

[42]  J. Davey,et al.  Cytotoxic T cells recognize fragments of the influenza nucleoprotein , 1985, Cell.

[43]  L. Old,et al.  T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[44]  B. Mukherji,et al.  Clonal analysis of cytotoxic T cell response against human melanoma , 1983, The Journal of experimental medicine.

[45]  G. Bonnard,et al.  Specific cytotoxicity against autologous tumour and proliferative responses of human lymphocytes grown in interleukin 2 , 1982, International journal of cancer.

[46]  R. Sheppard,et al.  Peptide synthesis. Part 2. Procedures for solid-phase synthesis using Nα-fluorenylmethoxycarbonylamino-acids on polyamide supports. Synthesis of substance P and of acyl carrier protein 65–74 decapeptide , 1981 .

[47]  C. Uyttenhove,et al.  Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis , 1980, The Journal of experimental medicine.

[48]  C. Barnstable,et al.  Molecular structure of human histocompatibility antigens: the HLA‐C series , 1977, European journal of immunology.